31 related articles for article (PubMed ID: 3661706)
1. Role for the cholecystokinin-A receptor in fever: a study of a mutant rat strain and a pharmacological analysis.
Ivanov AI; Kulchitsky VA; Romanovsky AA
J Physiol; 2003 Mar; 547(Pt 3):941-9. PubMed ID: 12562931
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin octapeptide improves cardiac function by activating cholecystokinin octapeptide receptor in endotoxic shock rats.
Zhao XY; Ling YL; Li YG; Meng AH; Xing HY
World J Gastroenterol; 2005 Jun; 11(22):3405-10. PubMed ID: 15948246
[TBL] [Abstract][Full Text] [Related]
3. Differential mechanism and site of action of CCK on the pancreatic secretion and growth in rats.
Yamamoto M; Otani M; Jia DM; Fukumitsu K; Yoshikawa H; Akiyama T; Otsuki M
Am J Physiol Gastrointest Liver Physiol; 2003 Oct; 285(4):G681-7. PubMed ID: 12801885
[TBL] [Abstract][Full Text] [Related]
4. Effect of cholecystokinin octapeptide on diacylglycerol-PKC signaling pathway in rat pulmonary interstitial macrophages stimulated by lipopolysaccharide.
Xu SJ; Gao WJ; Cong B; Ma CL; Li SJ; Ling YL; Gu ZY; Yao YX
Acta Pharmacol Sin; 2005 Dec; 26(12):1497-504. PubMed ID: 16297350
[TBL] [Abstract][Full Text] [Related]
5. The effect of cholecystokinin peptides on ovine duodeno-jejunal slow waves with and without pretreatment with proglumide.
Romański KW
J S Afr Vet Assoc; 2007 Dec; 78(4):209-14. PubMed ID: 18507220
[TBL] [Abstract][Full Text] [Related]
6. Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor.
Nadella S; Burks J; Al-Sabban A; Inyang G; Wang J; Tucker RD; Zamanis ME; Bukowski W; Shivapurkar N; Smith JP
Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G699-G712. PubMed ID: 29927319
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous infusion of proglumide on ruminal motility in conscious sheep (Ovis aries).
Onaga T
Vet Res Commun; 2007 Nov; 31(8):1021-36. PubMed ID: 17279465
[TBL] [Abstract][Full Text] [Related]
8. Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation.
Wu SV; Harikumar KG; Burgess RJ; Reeve JR; Miller LJ
Am J Physiol Gastrointest Liver Physiol; 2008 Sep; 295(3):G641-7. PubMed ID: 18776046
[TBL] [Abstract][Full Text] [Related]
9. Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
Rabiee A; Gay MD; Shivapurkar N; Cao H; Nadella S; Smith CI; Lewis JH; Bansal S; Cheema A; Kwagyan J; Smith JP
Clin Pharmacol Ther; 2022 Dec; 112(6):1271-1279. PubMed ID: 36087237
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic.
Jolly G; Duka T; Shivapurkar N; Chen W; Bansal S; Cheema A; Smith JP
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345148
[TBL] [Abstract][Full Text] [Related]
11. Potency of CR 1409, a new proglumide analog, on cholecystokinin-mediated behaviors and receptor binding.
Kaltwasser MT; Petrack B; Crawley JN
Neurochem Int; 1987; 10(4):547-53. PubMed ID: 20501129
[TBL] [Abstract][Full Text] [Related]
12. The Role of a Cholecystokinin Receptor Antagonist in the Management of Chronic Pancreatitis: A Phase 1 Trial.
Ciofoaia V; Chen W; Tarek BW; Gay M; Shivapurkar N; Smith JP
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794273
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment.
Brabez N; Nguyen KL; Saunders K; Lacy R; Xu L; Gillies RJ; Lynch RM; Chassaing G; Lavielle S; Hruby VJ
Bioorg Med Chem Lett; 2013 Apr; 23(8):2422-5. PubMed ID: 23489620
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment.
Malchiodi ZX; Cao H; Gay MD; Safronenka A; Bansal S; Tucker RD; Weinberg BA; Cheema A; Shivapurkar N; Smith JP
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638432
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Cholecystokinin-Secretory Peptides Using Bidirectional Long Short-term Memory Model Based on Transfer Learning and Hierarchical Attention Network Mechanism.
Liu J; Chen P; Song H; Zhang P; Wang M; Sun Z; Guan X
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759772
[TBL] [Abstract][Full Text] [Related]
16. Insulation of a G protein-coupled receptor on the plasmalemmal surface of the pancreatic acinar cell.
Roettger BF; Rentsch RU; Hadac EM; Hellen EH; Burghardt TP; Miller LJ
J Cell Biol; 1995 Aug; 130(3):579-90. PubMed ID: 7622559
[TBL] [Abstract][Full Text] [Related]
17. L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.
Hosotani R; Chowdhury P; Rayford PL
Dig Dis Sci; 1989 Mar; 34(3):462-7. PubMed ID: 2646088
[TBL] [Abstract][Full Text] [Related]
18. Receptor-mediated internalization and secretion of cholecystokinin into rat pancreatic duct fluid.
Izzo RS; Praissman M
Am J Physiol; 1987 Oct; 253(4 Pt 1):G445-51. PubMed ID: 3661706
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
